INTRODUCTION
ARSs (aminoacyl-tRNA synthetases) are essential enzymes for protein synthesis, conjugating amino acids to their cognate tRNAs. In higher eukaryotes, nine different ARSs form a MSC (multi-tRNA synthetase complex) comprising non-enzymatic factors and AIMPs (ARS-interacting multifunctional proteins) [1] . The three AIMPs, AIMP1/p43, AIMP2/p38 and AIMP3/p18, function as scaffolding proteins for the assembly and integrity of the MSC. However, they are capable of dissociating from the MSC whereupon they participate in various regulatory pathways [1] .
Among the AIMPs, AIMP2, which consists of four exons, is a potent tumour suppressor, which triggers growth-arrest signalling of TGF-β (transforming growth factor-β). This growth-arrest signalling occurs by its enhancement of ubiquitinmediated degradation of FBP (FUSE-binding protein), which is a transcriptional activator of the proto-oncogene Myc [2] . In addition, upon TNF-α (tumour necrosis factor-α) stimulation, AIMP2 induces cell apoptosis by facilitating ubiquitination of TRAF2 (TNF-receptor-associated factor 2) [3] . AIMP2 also reinforces pro-apoptotic signalling by protecting the tumour suppressor p53 from MDM2 (murine double minute 2)-mediated degradation under DNA damage stress [4] . The anti-proliferative and pro-apoptotic roles of AIMP2 have been supported by an in vivo mouse model, whereby Aimp2-heterozygous mice, as compared with wild-type mice, were shown to be more vulnerable to tumorigenesis in lung, colon and skin carcinogenesis xenograft models [5] .
Interestingly, AIMP2-DX2, an isoform of AIMP2 in which exon2 is deleted by alternative splicing, has been detected in cancer cell lines and tissues [6] . Like AIMP2, AIMP2-DX2 binds to FBP, TRAF2 and p53; however, it competes with AIMP2 for binding to these target proteins, consequently inhibiting the tumour-suppressive roles of AIMP2 [6, 7] . The expression ratio of AIMP2-DX2 to AIMP2 positively correlates with the malignancy of lung cancers in patients, as well as chemoresistance of ovarian cancer [6, 7] . These data suggest that AIMP2-DX2 might be an attractive target for developing cancer therapeutics.
Lung cancer is one of the most frequently occurring cancer types in humans, and is the leading cause of cancer-related death worldwide [8] . The need for an effective anti-lung cancer drug is obvious; however, current lung cancer treatment is principally dependent on cytotoxic drugs. Only a few targeted drugs are available to treat lung cancer due to the poor understanding of the mechanism of lung carcinogenesis, and, as a result, effective targets are scarce [9] . Since the expression of AIMP2-DX2 adversely affects lung cancer progression and patient survival [6] , inhibitors of AIMP2-DX2 expression may prove effective therapeutic agents for lung cancer. Indeed, knockdown of AIMP2-DX2 in a lung cancer mouse model by RNAi has been shown to significantly suppress tumorigenesis in the lung [6] . However, an effective small-molecule inhibitor of AIMP2- DX2 has not yet been reported. In the present paper we report that a small molecule termed BC-DXI01 specifically inhibits the expression of AIMP2-DX2 through down-regulation of its mRNA transcript, and we show the molecule has anti-tumorigenic activity in an in vivo mouse model.
EXPERIMENTAL
An expanded Experimental section is available in the Supplementary Online Information (at http://www.biochemj.org/ bj/454/bj4540411add.htm).
Compounds
A total of 2231 small compounds were sorted from ChemDiv's synthetic chemical library to maximize the coverage of structural diversity. To prepare BC-DXI01, ethyl 3-chloro-3-oxopropanoate (13.4 g, 0.089 mol) and triethylamine (1.25 ml, 0.089 mol) were added to a mixture of 4-aminobenzoic acid (10.0 g, 0.073 mol) in acetone (200 ml). The reaction mixture was stirred at room temperature (25
• C) for 4 h, and all volatiles were removed under reduced pressure. The residue was dissolved in water and acidified to pH 3 with concentrated HCl, the resulting precipitates were filtered and collected as an off-white solid (13.0 g, 75 % 
Small compound screening based on the luciferase assay
The AIMP2-DX2 gene was cloned into the pGL2 control vector by HindIII digestion to generate luciferase-tagged protein. pGL2-AIMP2-DX2 was transfected into cell lines using Fugene HD (Roche), according to the manufacturer's instructions. After a 12 h incubation, cells were counted and seeded into 96-well plates (10 4 cells/well) and incubated for 12 h. A total of 2231 small compounds (ChemDiv) dissolved in DMSO were added to the pGL2-AIMP2-DX2-transfected H460 cell lines at a 10 μM concentration in serum-free medium. After a 4-h incubation, cells were lysed and analysed using a firefly luciferase assay system (Promega) to detect luminescence. The compounds which showed an over 40 % decrease in the luminescence of AIMP2-DX2 compared with the DMSO control were chosen. Selected compounds were further tested to monitor the cytotoxicity based on the MTT assay using WI-26 normal lung cells.
RT (reverse transcription)-PCR
Total RNA was isolated from cell lines or frozen tumour tissues using TRIzol ® (Invitrogen) and converted into cDNAs using Moloney murine leukaemia virus reverse transcriptase (Invitrogen) and random hexamers according to the manufacturer's guidelines. PCRs were performed with PCR master mix (Bioneer) using primer pairs of 5 -ATGCCGATGTACCAGGTAAAG-3 (forward) and 5 -CTTAAGGAGCTTGAGGGCCGT-3 (reverse) for the simultaneous detection of both AIMP2-F (full-length AIMP2) transcript (960 bp) and AIMP2-DX2 transcript (753 bp). The primers 5 -CTGGCCACGTGCAGGATTACGGGG-3 (forward) and 5 -AAGTGAATCCCAGCTGATAG-3 (reverse), were used to specifically detect AIMP2-DX2 transcript (231 bp). The β-actin gene was used as an internal control, and was amplified using the primer set of 5 -CCTTCCTGGGCATGGAGTCCT-3 (forward) and 5 -GGAGCAATGATCTTGATCTT-3 (reverse) generating a 202 bp PCR product. PCRs were carried out using the PCR thermocycler (TaKaRa) under the following conditions: initial denaturation at 94
• C for 2 min, 33 (for simultaneous detection of both AIMP2-F and AIMP2-DX2 transcripts) or 30 (for single AIMP2-F gene detection) cycles of amplification (denaturation at 94
• C for 30 s, annealing at 60 • C for 30 s and extension at 72
• C for 45 s), and extension at 72
• C for 5 min. The PCR products were electrophoresed on a 1.5 % agarose gel and stained with ethidium bromide.
Xenograft mice model
Animal experiments complied with the University Animal Care and Use Committee guidelines at Seoul National University. The tumour mass was obtained by subcutaneous injection of H460 cell lines in 5-week-old BALB/c Slc-nu SP nude male mice. Tumour mass was extracted and dissected to 3 mm ×3 mm × 3 mm fragments and subcutaneously transplanted into healthy mice using a trocar and allowed to grow. When the tumour mass volume reached 80-117 mm 3 , mice were divided into control and treatment groups (n = 8 per group), and vehicle or BC-DXI01 (50 mg/kg) was introduced via intraperitoneal (4 days) and intrasubcutaneous (24 days) injections. The vehicle was prepared by mixing 10 % DMSO and 90 % mixture (Tween 80/PEG 400/distilled water, 16:4:25, by vol.). Mice were monitored every day and tumour volumes and body weights were checked two times a week. After killing the mice, tumour weights were measured and subjected to IHC (immunohistochemistry).
RESULTS

Identification of compounds which reduce the cellular AIMP2-DX2 level
Since AIMP2-DX2 was previously suggested as a novel therapeutic target against NSCLC (non-small-cell lung cancer) [6] , we set up the firefly luciferase assay system to screen a chemical library (2231 chemicals) for small molecules that inhibit the cellular level of AIMP2-DX2 (see Supplementary Figure  S1 at http://www.biochemj.org/bj/454/bj4540411add.htm). In the screening system, H460 cells were transfected with pGL2-AIMP2-DX2 to express luciferase-tagged AIMP2-DX2 and four compounds were identified to reduce 
Specific suppression of the AIMP2-DX2 transcript by BC-DXI01
To examine the concentration-dependent inhibitory effect of BC-DXI01 on the AIMP2-DX2 level, 0.04, 0.4 and 4 μM BC-DXI01 or DMSO only were added to H460 cells transfected with pGL2-AIMP2-DX2. BC-DXI01 effectively reduced AIMP2-DX2 expression on the basis of luminescence ( Figure 2A ). The effect of BC-DXI01 on endogenous AIMP2-DX2 protein was also analysed by immunoblotting, and the same result was observed (see Supplementary Figure S2A at http://www.biochemj.org/bj/454/bj4540411add.htm). Since 0.4 μM BC-DXI01 provided a robust suppressive effect, we used 0.4 μM for additional experiments. Next, we monitored the duration of efficacy by treating H460 cells with BC-DXI01 for the indicated times and analysed the levels of AIMP2-DX2 by immunoblotting ( Figure 2B , upper panel). The AIMP2-DX2 level decreased significantly within 2 h, and decreased progressively to 32 P]UTP, and mixed with biotinylated BC-DXI01. The mixture was subjected to a filter-binding assay using streptavidin-coated membrane and the bound RNA was detected via autoradiography. (F) Each RNA fragment synthesized by in vitro transcription was mixed with biotinylated BC-DXI01, and pulled down (IP) using streptavidin beads. RNA was purified from the captured complex and detected via RT-PCR using specific primer pairs.
an almost undetectable level within 12 h after treatment. BC-DXI01 did not affect the cellular level of AIMP2-F, indicating that BC-DXI01 specifically suppresses AIMP2-DX2.
To see whether BC-DXI01 influences the level of the AIMP2-DX2 mRNA transcript, total RNA was extracted from the H460 cells, and the AIMP2-F and AIMP2-DX2 mRNA levels were analysed using RT-PCR with primer pairs which could simultaneously detect both AIMP2-F and AIMP2-DX2 transcripts. Interestingly, levels of the AIMP2-DX2 transcript were decreased from 2 h after BC-DXI01 treatment and continuously reduced as shown for AIMP2-DX2 protein levels. However, levels of the AIMP2-F transcript were unchanged by BC-DXI01 treatment ( Figure 2B , lower panel, top gel). PCR cycles were reduced to detect AIMP2-F only without saturation and the same result was observed ( Figure 2B , lower panel, upper middle gel). The effect of BC-DXI01 on the AIMP2-DX2 transcript was confirmed using the AIMP2-DX2-specific primers and the result showed that, unlike AIMP2-F, AIMP2-DX2 expression was specifically reduced by BC-DXI01 treatment ( Figure 2B , lower panel, lower middle gel). The reduction in the AIMP2-DX2 transcript level was observed from 30 min after chemical treatment, and steadily declined thereafter (see Supplementary Figure S2B ). When transcription was blocked by actinomycin D treatment, the degradation of AIMP2-DX2 mRNA was accelerated by BC-DXI01, showing a comparatively rapid reduction in AIMP2-DX2 mRNA compared with that of the actinomycin D-untreated cells (see Supplementary Figure S2C ).
Since AIMP2-DX2 is an alternative splicing variant of AIMP2, we examined whether BC-DXI01 modulates the splicing of AIMP2-DX2. As a control, we transfected H460 cells with the pGINT plasmid, which comprises a splicing cassette capable of reporting alternative splicing by the expression of GFP [10] . We also transfected the pGINT-exon2 and pGINT-exon2-A152G plasmids [6] , which are used for the monitoring of AIMP2-DX2-specific splicing. The fluorescence of GFP observed by the transfection of pGINT, pGINT-exon2 and pGINT-exon2-A152G was not affected by the treatment of BC-DXI01, suggesting that it is the mature mRNA transcript of AIMP2-DX2, but not the splicing process, that is the target of BC-DXI01 (see Supplementary Figure S2D ).
To test whether BC-DXI01 modulates the cellular level of mature AIMP2-DX2 mRNA, we designed a DNA hybridization probe which specifically recognizes the exon1-3 junction sequence of the mature AIMP2-DX2 transcript, and examined AIMP2-DX2 mRNA levels by Northern blotting. We observed reduced levels of mature AIMP2-DX2 transcript after BC-DXI01 treatment ( Figure 2C ). Taken together, these results suggest that the decrease in AIMP2-DX2 protein by BC-DXI01 is due to BC-DXI01-mediated degradation of the mature AIMP2-DX2 transcript.
To understand the mechanism of BC-DXI01-mediated degradation of the mature AIMP2-DX2 transcript, we synthesized RNA fragments of AIMP2 or the AIMP-DX2 transcript via in vitro transcription ( Figure 2D ) and examined the binding affinity of BC-DXI01 to each RNA fragment using a filter-binding assay. BC-DXI01 showed apparent association with the fragments of AIMP2-DX2 transcripts which contain the exon1-3 junction sequence. However, this association was not observed in DX2-f85 and AIMP2-f573, which lacked the exon1-3 junction sequence ( Figure 2E ). We confirmed interaction between BC-DXI01 and the RNA fragments with the exon1-3 junction sequence by pulling down the compound-RNA complex and performing RT-PCR ( Figure 2F ). Since BC-DXI01 specifically bound to AIMP2-DX2 RNA fragments with the exon1-3 junction sequence, we suggest that BC-DXI01-mediated degradation of the mature AIMP2-DX2 transcript may be induced by the direct binding of BC-DXI01 to the region spanning the exon1-3 junction of the AIMP2-DX2 transcript.
Effect of BC-DXI01 on lung cancer cells
To examine the effect of AIMP2-DX2 inhibition on the viability of lung cancer cells, H460 cells were treated with BC-DXI01 and harvested at 24, 48 and 72 h. Using the MTT assay, we found that cell death was proportional to the dosage and duration of BC-DXI01 treatment, with 40 % of treated cells viable at the maximal dosage of 4 μM and duration of 72 h of treatment while cell viability was maintained at nearly 100 % in the control group ( Figure 3A) . BC-DXI01-induced cell apoptosis was also confirmed by flow cytometry-based cell cycle analysis, which showed a dose-dependent increase in the sub-G 1 fraction ( Figure 3B ). In addition, we found that, in BC-DXI01-treated H460 cells, active caspase 3, a marker of apoptosis, was present in levels proportional to the concentration of BC-DXI01 treatments ( Figure 3C ). We also found that active caspase 3 levels were inversely correlated with expression of PARP-1 [poly(ADP-ribose) polymerase 1], a cell proliferation marker, and AIMP2-DX2 (see Supplementary Figure S3 at http://www.biochemj.org/bj/454/bj4540411add.htm). Furthermore, a thymidine incorporation assay showed BC-DXI01 mediated inhibition of H460 cell proliferation ( Figure 3D ). Taken together, these data suggest that BC-DXI01 inhibits the anti-apoptotic and pro-proliferative effects of AIMP2-DX2.
Positive correlation between AIMP2-DX2 levels and the pro-apoptotic activity of BC-DXI01
To determine the effects of BC-DXI01 in various NSCLC cell lines, and also to see whether its effect is affected by AIMP2-DX2, we analysed the cellular levels of AIMP2-DX2 in ten NSCLC cell lines, and compared them with that of the normal lung cell line WI-26. First, we found that, in BC-DXI01-untreated cell lines, H1972 and H1171 cells expressed similar levels of AIMP2-DX2 protein as the control, whereas the other eight lung cancer cell lines expressed higher than normal levels of AIMP-DX2 protein ( Figure 4A, top panel) . We then tested the effects of BC-DXI01 treatment, and found an obvious reduction in AIMP2-DX2 levels in all of the cancer cell lines, except for H1972 and H1171 cells in which AIMP2-DX2 levels were intrinsically low. Whereas AIMP2-DX2 levels varied to some small degree between the tested cell lines, AIMP2-F levels were not affected by BC-DXI01 treatment ( Figure 4A, middle gels) . A cell viability analysis using the MTT assay revealed that BC-DXI01-mediated cell death was apparent in almost all of the cell lines tested, except for WI-26, H1975, H1972 and H1171 cells ( Figure 4B ). The susceptibility to BC-DXI01-mediated cell death generally showed a positive correlation with the cellular levels of AIMP2-DX2, apart from some outliers ( Figure 4C) , suggesting that the apoptotic activity of BC-DXI01 mainly resulted from the suppression of AIMP2-DX2. 
Inhibitory effect of BC-DXI01 on tumorigenesis in vivo
To test the antitumour activity of BC-DXI01, we established a xenograft mouse model using H460 cells. Since BC-DXI01 did not show good solubility in water, we synthesized a sodium salt form of BC-DXI01 to improve its solubility. The salt form of BC-DXI01 induced degradation of the AIMP2-DX2 transcript with similar efficacy to BC-DXI01 (see Supplementary Figure S4A at http://www.biochemj.org/bj/454/bj4540411add.htm). After oncedaily administration of the salt form of BC-DXI01 for 28 days, mice were killed and tumour masses were analysed. Compared with the control group, tumour growth in the BC-DXI01-treated group was apparently inhibited ( Figure 5A ). Tumour volumes and weights were reduced by up to 60 % following BC-DXI01 treatment ( Figures 5B and 5C ). However, BC-DXI01 did not affect the body weights of treated mice (see Supplementary Figure S4B ). To see whether BC-DXI01 induced cell death in the tumour region, we monitored the activation of caspase 3 in the tumour region by IHC and found a significant increase in apoptotic cells, validating the apoptotic activity of BC-DXI01 in vivo ( Figure 5D ). A decrease in the cellular levels of AIMP2-DX2 and its mRNA transcript was also observed in the BC-DXI01-treated group (see Supplementary Figure S4C ). These results suggest that BC-DXI01-mediated AIMP2-DX2 suppression can retard tumour growth in vivo.
DISCUSSION
AIMP2 regulates the stability of well-known oncogenes and tumour suppressors via context-dependent protein-protein interactions. AIMP2-DX2 shows increased expression in cancers, and competes with AIMP2 in various signalling pathways to compromise the anti-tumorigenic activity of AIMP2. Thus targeting AIMP2-DX2 could provide an effective therapeutic strategy to treat cancer. In the present study, we performed a screening with 2231 chemical libraries to identify small chemicals that can reduce the levels of AIMP2-DX2 and identified BC-DXI01, which has a novel mechanism to reduce the AIMP2-DX2 mRNA transcript, resulting in anti-tumorigenic activity in vivo. By analysing AIMP2-DX2 levels in various NSCLC cell lines, we found that most tested NSCLC cells appear to require AIMP2-DX2 for their survival, except for a few exceptional cases. For instance, the viability of H1975 cells was not significantly affected, although BC-DXI01 treatment successfully suppressed the AIMP2-DX2 level. Perhaps AIMP2-DX2 levels can be also regulated via unknown mechanisms in some cancer cells. The impact of this oncogenic splicing variant on cell survival would need more investigation for better understanding of the AIMP2-DX2 roles in cancer biology.
BC-DXI01 showed specific inhibitory activity to AIMP2-DX2, but not to AIMP2. Interestingly, BC-DXI01 targets the mature mRNA transcript of AIMP2-DX2 and consequently functions as an RNA-interfering chemical molecule. It may induce specific degradation of the AIMP2-DX2 transcript through direct binding to the exon1-3 junction region, although other possibilities can also be considered that could explain the activity of BC-DXI01. The exact mode of action for BC-DXI01 awaits further investigation in molecular detail. Nonetheless, the present study suggests the possibility of chemical-mediated RNA regulation for the development of specific RNA-targeting therapy.
Splicing variants have been recognized as attractive cancer diagnostic markers and drug targets because the controlled switching between splicing variants is closely related to tumour progression [11] . CD44, Wilms' tumour 1, BRCA1/2 (breast cancer earlyonset 1/2), PSA (prostate-specific antigen), the kallikrein gene family, MDM2, the fibroblast growth factor receptor family and osteopontin are the representative genes where splicing regulation is linked to their function in various cancers [11, 12] . RNA and ribonucleoprotein complexes have received attention as new therapeutic targets, because disruption in their activities has been identified as the cause of numerous diseases [13] .
To date, the major obstacle for the development of RNAregulating therapies lies in the difficulty of delivering antisense oligonucleotides or siRNAs in a tissue-specific manner [13, 14] . Chemical-based therapeutics might help overcome this drawback, but, so far, only a few compounds which modulate the spliceosomal proteins or translational machinery have been developed to control alternative splicing of HIV-1 [13, 15] . Development of chemicals which can regulate the mature transcript of human mRNA may provide an opportunity for the control of human mRNA without delivery concerns. Optimizing the effects of BC-DXI01 and determining its working mechanism at the molecular level would contribute to the progress in developing pharmaceutical compounds to satisfy the unmet needs in target-based therapy.
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Northern blotting
Total RNA was isolated from BC-DXI01-treated H460 cells using TRIzol ® , and 50 μg of RNA was separated by agarose gel electrophoresis and then transferred to Hi-bond membranes (Amersham). After baking for 2 h at 80
• C, the membrane was processed using a Brightstar biodetect nonisotopic detection kit (Ambion) following the manufacturer's guidelines. To generate a DNA probe for AIMP2-DX2, PCR was performed with the primer pair 5 -ATGCCGATGTACCAGGTAAAG-3 (forward) and 5 -GTTTTCAGGCACGCTCTTGACCGAG-3 (reverse) and then the PCR product (284 bp) was conjugated with biotin as suggested in the BrightStar psoralen-biotin nonisotopic labelling kit (Ambion).
Immunoblotting
Cell lines treated with compounds were harvested at the times indicated. The cells were lysed with lysis buffer containing 50 mM Tris/HCl, pH 7.4, 150 mM NaCl, 0.5 % Triton X-100, 5 mM EDTA, 10 % glycerol and protease inhibitors (Calbiochem). Frozen tumour tissues were homogenized in the lysis buffer. The lysates were centrifuged at 10000 g for 30 min at 4
• C to obtain the supernatant and the protein concentration was determined using a Bio-Rad protein assay kit. For immunoblotting, 50 μg of protein lysate per sample was subjected to SDS/PAGE after being mixed with SDS/PAGE sample buffer and then transferred on to a PVDF membrane.
The PVDF membrane was blocked with 5 % (w/v) non-fat dried skimmed milk powder in TBST (10 mM Tris, pH 7.4, 10 mM NaCl and 0.1 % Tween 20), incubated with the primary antibody overnight at 4
• C, and the bound antibodies were detected with a HRP (horseradish peroxidase)-labelled secondary antibody using West-one TM solution (iNtRON, Korea). The monoclonal antibody recognizing both AIMP2-F and AIMP2-DX2 was purchased from Neomics (Korea), and anti-PARP-1 and anti-actin antibodies were obtained from Santa Cruz Biotechnology. Anti-tubulin antibody was purchased from Sigma.
MTT assay
H460 cells (1×10 4 cells) were seeded in 96-well plates and treated with compounds for the indicated times in 0.5 % serumcontaining medium. MTT (USB) stock solution (5 mg/ml) was 10-fold diluted and 10 μl of diluted solution was added to each well containing 200 μl of medium and incubated for 30 min. The precipitated crystal was dissolved in 100 μl of DMSO (Sigma). Absorbance was measured at 420 nm using a microplate reader (Sunrise, TECAN). 3 H]Thymidine at 1 μCi/ml was added to the culture medium and was incubated for 4 h. The incorporated thymidine was measured using a liquid scintillation counter (Wallac).
IHC
Dissected tumours were fixed and stored in 10 % neutralbuffered formalin. Tissues were processed, paraffin-embedded, and sectioned at 6 μm thickness. After deparaffinization, antigen retrieval was performed by boiling sections for 5 min in sodium citrate solution (0.01 M, pH 6). Sections were incubated at 4
• C overnight with rabbit anti-(active caspase 3) antibody (1:200 dilution, Cell Signaling Technology) in PBST (0.3 % Triton X-100 in PBS) containing 5 % goat serum. After washing, sections were incubated with biotin-conjugated anti-(rabbit IgG) (1:100 dilution, Sigma) antibody and ExtrAvidin-peroxidase (1:50 dilution, Sigma) at room temperature for 1 h each. Sections were developed with DAB (3, 3-diaminobenzidine) substrate for 30 min, counterstained with haematoxylin and imaged under the microscope.
In vitro transcription
To generate RNA fragments of AIMP2 and AIMP2-DX2 transcripts, PCR was performed with specific primers. A common forward primer with a T7 promoter sequence, 5 -TAATA-CGACTCACTATAATGCCGATGTACCAGGTAAAG-3 , was used for every reaction in combination with each reverse primer. Specific reverse primers, 5 -TGGGGAGCCGGTAC-ATGCAGGTGGG-3 , 5 -GGGGAGGCCGGGTTTGCGTTGAT-CA-3 , 5 -GTTTTCAGGCACGCTCTTGACCGAG-3 , 5 -GTT-GCGTTGACAGCATTATGCTTCT-3 , 5 -TCACTTAAGGAGC-TTGAGGGCCGTGTTAAA-3 and 5 -ATTCTTCCAAATTA-AAGTGAATCCC-3 , were used for the amplification of DX2-f85, DX2-f185, DX2-f285, DX2-f485, DX2-full and AIMP2-f573 respectively. Amplified PCR products were purified and RNA was synthesized by in vitro transcription using each PCR template and T7 RNA polymerase (Promega). For the filter-binding assay, RNA was radioactively labelled using [α-32 P]UTP.
Filter-binding assay (dot blot assay)
Biotinylated BC-DXI01 and radioactively labelled RNA (10000 c.p.m.) were incubated in the binding buffer (20 mM Tris/HCl, pH 7.4, 75 mM KCl, 10 mM MgCl 2 and 5 % glycerol) at room temperature for 30 min. The reaction mixtures were filtered through a streptavidin-coated matrix biotin-capture membrane (Promega) using a 96-well Minifold filtration apparatus. Dried membranes were exposed, and signals were detected by autoradiography.
Pull-down assay for BC-DXI01 and RNA complex
Synthesized RNA fragments (2 μg) were added to the biotinylated BC-DXI01 in the RNA-binding buffer (200 mM KCl, 20 mM NaCl, 0.05 % Nonidet P40, 10 % glycerol, 2 mM DTT, 2 mM MgCl 2 and 20 mM Hepes, pH 7.8), and incubated for 1 h at 30 • C. After cross-linking by the addition of 1 % formaldehyde at room temperature for 10 min, the RNA-BC-DXI01 complex was pulled down using streptavidin-Sepharose beads (1 h incubation with rotation). After washing and incubation with DNase I (Fermentas) to remove contaminating DNA, RNA was extracted with phenol/chloroform and precipitated by ethanol. Each RNA fragment was detected via RT-PCR using a common forward primer, 5 -ATGCCGATGTACCAGGTAAAG-3 , and the specific reverse primer described in the In vitro transcription section above. 
